Cosentyx (secukinumab) is a medication used to treat various inflammatory conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. The ideal level of Cosentyx depends on the specific condition being treated and the individual patient's response to the medication.

According to the drug patent watch website [1], the recommended dosage for Cosentyx varies depending on the condition being treated. For psoriasis, the recommended dose is 300 mg administered by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks. For psoriatic arthritis, the recommended dose is 150 mg or 300 mg administered by subcutaneous injection every 4 weeks. For ankylosing spondylitis, the recommended dose is 150 mg administered by subcutaneous injection every 4 weeks.

The Cosentyx website [2] also provides information on dosing for ankylosing spondylitis. According to the website, the recommended dose is 150 mg administered by subcutaneous injection every 4 weeks. The website notes that some patients may benefit from an increased dose of 300 mg every 4 weeks, based on their individual response to the medication.

Medscape [3] provides additional information on dosing for Cosentyx. According to the website, the recommended dose for psoriasis is 300 mg administered by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks. For psoriatic arthritis, the recommended dose is 150 mg or 300 mg administered by subcutaneous injection every 4 weeks. For ankylosing spondylitis, the recommended dose is 150 mg administered by subcutaneous injection every 4 weeks.

In conclusion, the ideal level of Cosentyx depends on the specific condition being treated and the individual patient's response to the medication. The recommended dosages for Cosentyx vary depending on the condition being treated, with dosages ranging from 150 mg to 300 mg administered by subcutaneous injection every 4 weeks. Patients should consult with their healthcare provider to determine the appropriate dose of Cosentyx for their individual needs.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.cosentyx.com/ankylosing-spondylitis/faq
[3] https://reference.medscape.com/drug/cosentyx-secukinumab-999964